HCM Valuation
HUTCHMED (China) Ltd
$
17.450
- Overview
- Forecast
- Valuation
- Earnings
HCM Relative Valuation
HCM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCM is overvalued; if below, it's undervalued.
Historical Valuation
HUTCHMED (China) Ltd (HCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.56 is considered Undervalued compared with the five-year average of 19.73. The fair price of HUTCHMED (China) Ltd (HCM) is between 17.72 to 42.34 according to relative valuation methord. Compared to the current price of 17.45 USD , HUTCHMED (China) Ltd is Undervalued By 1.5%.
Relative Value
Fair Zone
17.72-42.34
Current Price：17.45
1.5%
Undervalued
14.34
PE
1Y
3Y
5Y
Trailing
Forward
-468.90
EV/EBITDA
HUTCHMED (China) Ltd. (HCM) has a current EV/EBITDA of -468.90. The 5-year average EV/EBITDA is -52.09. The thresholds are as follows: Strongly Undervalued below -273.23, Undervalued between -273.23 and -162.66, Fairly Valued between 58.48 and -162.66, Overvalued between 58.48 and 169.05, and Strongly Overvalued above 169.05. The current Forward EV/EBITDA of -468.90 falls within the Strongly Undervalued range.
-217.53
EV/EBIT
HUTCHMED (China) Ltd. (HCM) has a current EV/EBIT of -217.53. The 5-year average EV/EBIT is -36.79. The thresholds are as follows: Strongly Undervalued below -137.80, Undervalued between -137.80 and -87.29, Fairly Valued between 13.71 and -87.29, Overvalued between 13.71 and 64.22, and Strongly Overvalued above 64.22. The current Forward EV/EBIT of -217.53 falls within the Strongly Undervalued range.
4.56
PS
HUTCHMED (China) Ltd. (HCM) has a current PS of 4.56. The 5-year average PS is 5.64. The thresholds are as follows: Strongly Undervalued below -2.41, Undervalued between -2.41 and 1.61, Fairly Valued between 9.66 and 1.61, Overvalued between 9.66 and 13.68, and Strongly Overvalued above 13.68. The current Forward PS of 4.56 falls within the Historic Trend Line -Fairly Valued range.
21.37
P/OCF
HUTCHMED (China) Ltd. (HCM) has a current P/OCF of 21.37. The 5-year average P/OCF is -66.40. The thresholds are as follows: Strongly Undervalued below -429.19, Undervalued between -429.19 and -247.80, Fairly Valued between 114.99 and -247.80, Overvalued between 114.99 and 296.39, and Strongly Overvalued above 296.39. The current Forward P/OCF of 21.37 falls within the Historic Trend Line -Fairly Valued range.
18.20
P/FCF
HUTCHMED (China) Ltd. (HCM) has a current P/FCF of 18.20. The 5-year average P/FCF is -22.82. The thresholds are as follows: Strongly Undervalued below -72.52, Undervalued between -72.52 and -47.67, Fairly Valued between 2.03 and -47.67, Overvalued between 2.03 and 26.88, and Strongly Overvalued above 26.88. The current Forward P/FCF of 18.20 falls within the Overvalued range.
HUTCHMED (China) Ltd (HCM) has a current Price-to-Book (P/B) ratio of 12.22. Compared to its 3-year average P/B ratio of 7.31 , the current P/B ratio is approximately 67.14% higher. Relative to its 5-year average P/B ratio of 6.54, the current P/B ratio is about 86.99% higher. HUTCHMED (China) Ltd (HCM) has a Forward Free Cash Flow (FCF) yield of approximately -1.67%. Compared to its 3-year average FCF yield of -2.63%, the current FCF yield is approximately -36.61% lower. Relative to its 5-year average FCF yield of -3.72% , the current FCF yield is about -55.16% lower.
12.22
P/B
Median3y
7.31
Median5y
6.54
-1.67
FCF Yield
Median3y
-2.63
Median5y
-3.72
Competitors Valuation Multiple
The average P/S ratio for HCM's competitors is 14.53, providing a benchmark for relative valuation. HUTCHMED (China) Ltd Corp (HCM) exhibits a P/S ratio of 4.56, which is -68.60% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HCM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HCM in the past 1 year is driven by Unknown.
People Also Watch
RPD
Rapid7 Inc
20.180
USD
+3.49%
SEM
Select Medical Holdings Corp
12.630
USD
+2.93%
WULF
Terawulf Inc
11.170
USD
-1.59%
CDE
Coeur Mining Inc
16.280
USD
+1.75%
CURB
Curbline Properties Corp.
22.700
USD
+1.16%
FBK
FB Financial Corp
54.290
USD
+2.80%
BKE
Buckle Inc
61.170
USD
+1.14%
WAFD
WaFd Inc
31.830
USD
+2.35%
MPW
Medical Properties Trust Inc
5.040
USD
+1.61%
GCMG
GCM Grosvenor Inc
13.120
USD
+1.86%
FAQ
Is HUTCHMED (China) Ltd (HCM) currently overvalued or undervalued?
HUTCHMED (China) Ltd (HCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.56 is considered Undervalued compared with the five-year average of 19.73. The fair price of HUTCHMED (China) Ltd (HCM) is between 17.72 to 42.34 according to relative valuation methord. Compared to the current price of 17.45 USD , HUTCHMED (China) Ltd is Undervalued By 1.50% .
What is HUTCHMED (China) Ltd (HCM) fair value?
How does HCM's valuation metrics compare to the industry average?
What is the current P/B ratio for HUTCHMED (China) Ltd (HCM) as of Sep 18 2025?
What is the current FCF Yield for HUTCHMED (China) Ltd (HCM) as of Sep 18 2025?
What is the current Forward P/E ratio for HUTCHMED (China) Ltd (HCM) as of Sep 18 2025?